New York, April 9, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces Release of Type 1 Diabetes Report – Global Drug Forecast and Market Analysis to 2029 – https://www.reportlinker.com/p06058302/? utm_source = GNW
Insulin is the hormone that is needed to move glucose from the blood to the cells. Without this insulin, the body becomes hyperglycemic.
If left untreated, this leads to death. There is no cure for T1D and it is treated as a chronic condition by injections of exogenous insulin.
There are other types of diabetes such as type 2 diabetes (developed insulin resistance), gestational diabetes, latent autoimmune diabetes in adults, and diabetes which is a symptom of other diseases. This report focuses on T1D.
The introduction of the first disease-modifying therapeutics will be the main growth drivers in the forecast period. Teplizumab, the first preventive therapeutic for T1D, is expected to be launched in the United States during the forecast period. Other important drivers for the T1D market are the increased T1D-diagnosed prevalence and the inclusion of new types of ultra-fast-acting and ultra-long-acting insulin analogues.
Based on the epidemiological analysis, diagnosed cases of T1D in the 8MM will increase by 17.79% over the next decade, from 3,329,294 cases in 2019 to 3,921,695 cases in 2029 with an annual growth rate (AGR) of 1.78% per year annually in the eight major pharmaceutical markets (8MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain and the UK), Japan and Canada.
The analyst predicts that the therapeutic market for T1D will grow within $ 8 million from $ 4.9 billion in 2019 at a significant average annual growth rate (CAGR) of 17.2% to $ 24 billion by 2029. In particular, the analyst expects the US market to be the largest contributor to the growth of the T1D market, with sales of $ 4.3 billion in 2019 (87.7% of the T1D market) and sales of 2029 in 2029 Contribute $ 3 billion (84.7% of the T1D market).
The doctors surveyed agreed with regard to the current treatment landscape that while there are a number of insulin treatment options, there are significant numbers of patients who are treated ineffectively and therefore have a considerably high unmet need within the indication. Key Opinion Leaders (KOLs) surveyed the lack of a non-disease-modifying therapeutic agent that combats autoimmune-mediated attack by beta cells in T1D patients.
Other important topics include controlling blood sugar, fighting obesity, and general disease management. Despite a number of drugs currently in development, research suggests that future achievement of these unmet needs will be modest and that there are relatively many opportunities for drug developers to enter the T1D market.
Key highlights
– The diagnosed prevalence of T1D is expected to increase over the 10 year forecast period due to changing population demographics and a better understanding of the risk and environmental factors that can trigger the onset of T1D.
– The possible introduction of 5 disease-modifying therapeutics will increase the number of patients who can prolong their endogenous insulin secretion at the time of diagnosis to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that contributes to their remarkable return on investment.
– The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that are successful in the marketplace. The trend towards closed loop systems such as an artificial pancreas requires a great deal of ultrafast insulins to be brought to market and leads to closer collaboration between industries.
– Despite the multitude of insulins currently available to T1D patients, there is still room for improvement in the treatment room. Most noticeable is the need for novel treatment options for refractory patients.
IMPORTANT QUESTIONS ANSWERED
Despite the existence of numerous well-established treatment options in the T1D room, a few unmet needs remain.
– Which unmet needs are most urgent at 8MM?
– Where should pharmaceutical companies focus their drug development efforts in order to become a major player in this area?
Novel insulins continue to be developed, and the first disease-modifying therapeutics could hit the market during the forecast period.
– What are the most promising late-stage candidates and how much do they expect in the forecast period?
– What do KOLs say about their clinical and commercial positioning?
The T1D market has been dominated by three major companies since the discovery of insulin 100 years ago, although new players have emerged more recently.
– Which companies have historically been leaders?
– Which new companies are emerging in the area?
scope
– Overview of T1D including epidemiology, disease cause and management.
Top-line T1D drug market sales (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and projected sales for key late-stage drugs in the pipeline.
– Key topics covered include assessing current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, EU 5, Japan and Canada over the 10 year forecast period.
– Pipeline Analysis: New trends in the development and detailed analysis of late-stage drugs in the pipeline.
– To analyze the current and future market competition in the global Angina Pectoris Therapeutics Market. Insightful review of key industry drivers, restraints, and challenges.
Reasons to buy
With the report you can –
– Develop and draft your in-licensing and out-licensing strategies. Use a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
– Develop business strategies by understanding the trends shaping and driving the global T1D Therapeutics Market.
– Increase your sales by understanding the key trends, innovative products and technologies, market segments, and companies that are expected to impact the global T1D Market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of different competitors.
– Identify emerging players with potentially strong product portfolios and develop effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global T1D Therapeutics Market from 2019 to 2029.
– Organize your sales and marketing efforts by identifying the market categories and segments that offer maximum opportunities for consolidation, investment and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06058302/?utm_source=GNW
Via report linker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need in one place, instantly.
__________________________
